BN

Bionik Laboratories CorpOOTC BNKL Stock Report

Last reporting period 31 Mar, 2023

Updated —

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

BNKL Stock Analysis

BN

Uncovered

Bionik Laboratories Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-43/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

350.62 B

Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. The company is headquartered in Watertown, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2012-06-12. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and deliver recovery for patients with neurological or mobility impairments. The company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. Its InMotion ARM, and InMotion ARM/HAND products are robotic therapies for the upper limbs. In addition to these fully developed, clinical rehabilitation solutions, it is also developing InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. Its other products are InMotion Robots and InMotion CONNECT.

View Section: Eyestock Rating